You are here
Coronary side effects dash Amgen, UCB hopes for osteoporosis drug
AMGEN Inc and UCB SA no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.
The drug, romosozumab, which would be sold under the brand name
- CALL +65 6388 3838
- EMAIL email@example.com